Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 8C-101, Bethesda, Maryland 20892, USA.
Endocr Relat Cancer. 2010 May 18;17(2):513-24. doi: 10.1677/ERC-09-0272. Print 2010 Jun.
The hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a familial cancer syndrome that can result from germline inactivation of HRPT2/CDC73, a putative tumor suppressor gene that encodes parafibromin, a component of the transcriptional regulatory PAF1 complex with homology to the yeast protein Cdc73p. The vast majority of HRPT2/CDC73 germline mutations identified have been truncation or frameshift mutations, and loss of function due to missense mutation is rare. We report here a kindred with HPT-JT due to a germline L95P missense mutation in parafibromin. The mutant parafibromin was studied in vitro to understand the basis of its presumed loss-of-function. When transfected in cultured cells, the L95P mutant was expressed to a lower level than wild-type (wt) parafibromin, a difference that was not overcome by inhibition of the proteasomal degradation pathway. The L95P mutant parafibromin retained the ability to assemble with endogenous PAF1 complex components as evidenced by co-immunoprecipitation. Analysis of subcellular localization showed that the L95P mutant was markedly deficient in nucleolar localization compared to the wt, an impairment likely resulting from disruption of a putative nucleolar localization signal immediately upstream of the L95P mutation. Transfection of the L95P parafibromin mutant, but not the wt, enhanced cell cycle progression and increased cell survival in NIH-3T3 and HEK 293 cells, resulting apparently from dominant interference with endogenous parafibromin action. The simultaneous loss of nucleolar localization and acquisition of a growth stimulatory phenotype with the L95P mutation raise the possibility that parafibromin must interact with targets in the nucleolus to fully execute its tumor suppressor functions.
甲状旁腺功能亢进-颌骨肿瘤综合征(HPT-JT)是一种家族性癌症综合征,可由 HRPT2/CDC73 的种系失活引起,HRPT2/CDC73 是一种假定的肿瘤抑制基因,编码 parafibromin,它是转录调节 PAF1 复合物的一个组成部分,与酵母蛋白 Cdc73p 具有同源性。绝大多数鉴定的 HRPT2/CDC73 种系突变是截断或移码突变,由于错义突变导致功能丧失的情况很少见。我们在这里报告一个家族患有 HPT-JT,其原因是 parafibromin 中的种系 L95P 错义突变。体外研究了突变的 parafibromin,以了解其假定的失活功能的基础。当在培养的细胞中转染时,L95P 突变体的表达水平低于野生型(wt)parafibromin,这种差异不能通过抑制蛋白酶体降解途径来克服。L95P 突变体 parafibromin 仍然能够与内源性 PAF1 复合物成分组装,这一点可以通过共免疫沉淀证明。亚细胞定位分析表明,与 wt 相比,L95P 突变体在核仁中的定位明显不足,这种缺陷可能是由于 L95P 突变上游的假定核仁定位信号被破坏所致。转染 L95P 突变体 parafibromin,但不是 wt,增强了 NIH-3T3 和 HEK 293 细胞的细胞周期进程并增加了细胞存活,这显然是由于对内源性 parafibromin 作用的显性干扰。L95P 突变同时丧失核仁定位并获得生长刺激表型,这表明 parafibromin 必须与核仁中的靶标相互作用才能充分发挥其肿瘤抑制功能。